I
Isarna Therapeutics
Develop selective TGF-β inhibitors to effectively treat ophthalmic diseases
About Isarna Therapeutics
Isarna Therapeutics is a biotechnology company specializing in the development of antisense therapies aimed at blocking the production of TGF Beta, a key mediator of fibrosis in the eye and other organs such as the liver and lung. The company operates in the biopharmaceutical market, focusing on innovative treatments for conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Isarna's business model revolves around advancing its pipeline of antisense molecules through clinical trials, with the goal of bringing these therapies to market. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company serves patients suffering from fibrotic diseases and eye conditions, as well as the broader medical community engaged in treating these ailments.
Source: Dealroom company dataNews
Open roles
Isarna Therapeutics in the Munich ecosystem
The Isarna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
MIG Capital
Series B and later1 investor entered at this stage
Global Asset Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Isarna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Isarna Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


